GeneThera, Inc.
GTHR · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $1 | $1 | $4 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$0 |
| Other Operating Expenses | $0 | $0 | $0 | $3 |
| Operating Expenses | $1 | $1 | $1 | $4 |
| Operating Income | -$1 | -$1 | -$1 | -$4 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | -$0 | $0 | $1 |
| Pre-Tax Income | -$1 | -$1 | -$1 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$1 | -$1 | -$4 |
| % Margin | – | – | – | – |
| EPS | -0.04 | -0.04 | -0.015 | -0.11 |
| % Growth | -0.5% | -161.8% | 86.2% | – |
| EPS Diluted | -0.04 | -0.04 | -0.015 | -0.11 |
| Weighted Avg Shares Out | 25 | 20 | 36 | 38 |
| Weighted Avg Shares Out Dil | 25 | 20 | 36 | 38 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | -$0 | -$3 |
| % Margin | – | – | – | – |